Publications by authors named "J N Pouw"
The epigenome of leukemic cells is dysregulated, and genes required for cell cycle arrest and differentiation may become repressed, which contributes to the accumulation of undifferentiated malignant blood cells. Here, we show that the Polycomb group protein CBX7 can interact with H3K9 methyltransferases EHMT1/2 and SETDB1. We aimed to assess whether combined interfering with these H3K9 methyltransferases and CBX7 could derepress target genes and thereby induce growth arrest of leukemic cells.
View Article and Find Full Text PDFArticle Synopsis
- This study looks at a new imaging tracer called [F]F-AraG, which helps scientists understand how cancer and the immune system interact, particularly in lung cancer patients.
- Researchers tested this tracer in 13 patients to figure out the best way to measure how much of it gets taken up by tumors over time.
- The results showed that the 2T3k model was the best for understanding how the tracer works, and two specific measurements (TBR and TPR) were very useful for comparing results across different time periods.
Introduction: Immune checkpoint inhibitors (ICIs) can elicit anticancer immune responses, but predictive biomarkers are needed. We measured programmed death ligand 1 (PD-L1) expression in organs and lymph nodes using F-BMS-986192 positron emission tomography (PET)-imaging and looked for correlations with response and immune-related adverse events.
Methods: Four F-BMS-986192 PET studies in patients with melanoma, lung, pancreatic and oral cancer, receiving ICI treatment, were combined.
Background: PET scans using zirconium-89 labelled monoclonal antibodies (Zr-mAbs), known as Zr-immuno-PET, are made to measure uptake in tumour and organ tissue. Uptake is related to the supply of Zr-mAbs in the blood. Measuring activity concentrations in blood, however, requires invasive blood sampling.
View Article and Find Full Text PDFArticle Synopsis
- In patients with locally advanced unresectable NSCLC, the study examines how concurrent chemoradiotherapy (CRT) affects the uptake of the anti-PD-L1 antibody durvalumab, especially its expression in tumors and surrounding healthy organs.
- Results show that a high percentage of tumor lesions were initially positive for the antibody, but this positive detection decreased during treatment, suggesting changes in PD-L1 expression.
- The research highlights variability in tracer uptake, with notable changes observed in bone marrow and spleen uptake during CRT, indicating potential impacts of therapy on organ response.